Literature DB >> 3290010

Prospective study of predictors of beta-cell survival in type I diabetes.

A Schiffrin1, S Suissa, P Poussier, R Guttmann, G Weitzner.   

Abstract

We conducted a prospective study to describe the course of the pancreatic beta-cell function from the time of clinical diagnosis of insulin-dependent (type I) diabetes to determine whether DR type, presence of islet cell antibodies (ICA), presence of insulin antibodies (IA), age at onset, and sex could help in the prediction of residual endogenous insulin secretion. A cohort of 68 children was followed for 18 mo after diagnosis of type I diabetes. The outcome variables selected for analysis were 1) serum C-peptide peak concentration after a Sustacal meal, 2) time of disappearance of the serum C-peptide response, and 3) time after diagnosis at which the maximal serum C-peptide response was observed. After institution of insulin therapy, serum C-peptide peak concentrations rose temporarily for 1-6 mo and declined thereafter. Multivariate analysis of the data showed that DR type (P = .2488) and presence of IA (P = .1604) had no effect on serum C-peptide over time, but sex (P = .0146), age at onset (P = .0002), and presence of ICA (P = .0147) significantly contributed to the variation of serum C-peptide over time. Furthermore, age at onset, presence of ICA, and sex were also the only significant predictors of the time of disappearance of the beta-cell function. The relative risks of beta-cell-function disappearance were 0.87 (P = .0015), 9.43 (P = .0181), and 2.25 (P = .0468), respectively. In conclusion, there are distinct variations in the natural course of the beta-cell function in type I diabetes. beta-Cell-function survival is significantly shortened the younger the subject is at disease onset, if ICA are present at diagnosis, and if the subject is male.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3290010     DOI: 10.2337/diab.37.7.920

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  6 in total

1.  HLA antigens in Spanish type 1 diabetic population. Correlations with clinical, biological and autoimmune markers.

Authors:  A Goday; E Motaña; G Ercilla; J Fernandez; R Gomis; E Vilardell
Journal:  Acta Diabetol Lat       Date:  1990 Jul-Sep

2.  Association of adiponectin, interleukin (IL)-1ra, inducible protein 10, IL-6 and number of islet autoantibodies with progression patterns of type 1 diabetes the first year after diagnosis.

Authors:  A Kaas; C Pfleger; L Hansen; K Buschard; N C Schloot; B O Roep; H B Mortensen
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

3.  Cell type-specific immune phenotypes predict loss of insulin secretion in new-onset type 1 diabetes.

Authors:  Matthew J Dufort; Carla J Greenbaum; Cate Speake; Peter S Linsley
Journal:  JCI Insight       Date:  2019-02-21

4.  Proinsulin and C-peptide at onset and during 12 months cyclosporin treatment of type 1 (insulin-dependent) diabetes mellitus.

Authors:  O Snorgaard; S G Hartling; C Binder
Journal:  Diabetologia       Date:  1990-01       Impact factor: 10.122

5.  Case Reports That Illustrate the Efficacy of SGLT2 Inhibitors in the Type 1 Diabetic Patient.

Authors:  David S H Bell
Journal:  Case Rep Endocrinol       Date:  2015-02-16

6.  The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes.

Authors:  Sam Tsz Wai Cheng; Lihua Chen; Stephen Yu Ting Li; Eric Mayoux; Po Sing Leung
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.